PolyModels Hub has raised £7m in a Series A round from Molten Ventures and Marathon Venture Capital. The funding will support the company’s goal of accelerating the digital transformation of biopharma process development.
PolyModels Hub is changing the way pharmaceutical companies develop and manufacture medicines. Its platform, built by experts for pharma teams, brings advanced modelling, simulation, and workflow management together in one digital hub. The technology enables scientists and engineers to design, test, and improve drug development processes faster and more efficiently, helping companies save time, reduce costs, and deliver better medicines.
Already trusted by four of the world’s top ten pharmaceutical companies, PolyModels Hub has quickly established itself as a critical enabler of modern drug development. Its platform is delivering measurable results, with the potential to save hundreds of millions of pounds per drug by streamlining and accelerating process development.
The new investment will allow the company to expand its engineering and product teams, enhance its core platform, and reach more pharma companies worldwide. The team will continue building scalable solutions for process and regulatory workflows, making it easier for customers to adopt and benefit from the technology.
